Abstract
A new era in migraine prophylaxis has begun with the launch of antibodies blocking the Calcitonin-Gene Related Peptide (CGRP) pathway. These substances act across the entire frequency spectrum of migraine and have a tolerability superior to any other class of migraine preventatives based on our clinical and experimental knowledge of a 5- year period of use. Their superior tolerability profile may be due to their specificity. New questions have also arrived with these drugs ranging from the duration of therapy and treatment pause to the question which monoclonal antibodies (mAb) for which patient - a question which we cannot answer at this stage. Nevertheless, CGRP – ® mAbs offer a class of migraine prophylactics with significant advantages over older medications.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
